Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) has been given a consensus rating of “Buy” by the nineteen brokerages that are presently covering the stock, American Banking and Market News reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $92.24.

Shares of Edwards Lifesciences Corp (NYSE:EW) opened at 98.26 on Monday. Edwards Lifesciences Corp has a one year low of $60.62 and a one year high of $99.35. The stock has a 50-day moving average of $91.97 and a 200-day moving average of $81.62. The company has a market cap of $10.419 billion and a P/E ratio of 14.07.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.88 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter last year, the company posted $0.82 earnings per share. Edwards Lifesciences Corp’s revenue was up 11.2% compared to the same quarter last year. Analysts expect that Edwards Lifesciences Corp will post $3.29 EPS for the current fiscal year.

A number of research firms have recently commented on EW. Analysts at Zacks reiterated a “neutral” rating on shares of Edwards Lifesciences Corp in a research note on Wednesday. They now have a $104.00 price target on the stock. Separately, analysts at JMP Securities raised their price target on shares of Edwards Lifesciences Corp from $97.00 to $120.00 in a research note on Thursday, August 21st. They now have an “outperform” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st.

In other Edwards Lifesciences Corp news, VP Carlyn D. Solomon unloaded 85,200 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $97.85, for a total transaction of $8,336,820.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.